自发性蛛网膜下腔出血患者尼莫地平治疗相关的血压变化
这项观察性队列研究纳入2010至2021年一家三级中心连续收治的自发性蛛网膜下腔出血(SAH)患者,静脉组271例、口服组49例,均接受预防性尼莫地平并持续血压监测。静脉尼莫地平起始后30%(81/271)患者收缩压下降>10%,最大效应在15分钟;口服尼莫地平601次摄入中53次(9%)出现收缩压下降>10%,最大效应在30-45分钟。静脉起始后1小时内50%(136/271)需启动或增加去甲肾上腺素,9%(25/271)使用胶体;口服前后去甲肾上腺素使用率分别为3%和4%。静脉或口服后均未观察到收缩压<90 mm Hg的低血压发作。多因素分析仅基线收缩压较高与静脉(p<0.001)或口服(p=0.001)后收缩压下降>10%相关。
要点
- 静脉尼莫地平起始后30%(81/271)患者收缩压下降>10%,最大效应在15分钟,1小时内50%(136/271)需启动或增加去甲肾上腺素。
- 口服尼莫地平601次摄入中53次(9%)出现收缩压下降>10%,最大效应在30-45分钟,28/49(57%)患者出现该效应。
- 静脉或口服尼莫地平后均未观察到收缩压<90 mm Hg的低血压发作。
- 多因素分析仅基线收缩压较高与静脉(p<0.001)或口服(p=0.001)后收缩压下降>10%相关。
- 作者认为早期识别并用升压药或液体对抗似乎是必要的,以预防低血压发作。
适用人群与场景
- 2010至2021年一家三级中心连续收治的自发性蛛网膜下腔出血患者,静脉组271例、口服组49例,均接受预防性静脉或口服尼莫地平。
诊断标准与关键阈值
- 显著血压变化定义为收缩压或舒张压较基线(尼莫地平给药前30分钟中位数)下降>10%。
处置流程与药物剂量
- 静脉尼莫地平起始后1小时内,136/271(50%)患者需启动或增加去甲肾上腺素,25/271(9%)患者使用胶体。
- 口服尼莫地平前后去甲肾上腺素使用率分别为3%和4%。
研究设计与关键结果
- 观察性队列研究,纳入2010至2021年一家三级中心连续收治的SAH患者,静脉组271例、口服组49例,均接受预防性尼莫地平并持续血压监测。
- 入院中位Hunt & Hess评分为3(2-5;静脉组3[2-5],口服组1[1-2],p<0.001),年龄58(49-69)岁。
- 静脉尼莫地平起始后30%(81/271)患者收缩压下降>10%,最大效应在15分钟。
- 静脉尼莫地平起始后1小时内,136/271(50%)患者需启动或增加去甲肾上腺素,25/271(9%)患者使用胶体。
- 口服尼莫地平601次摄入中53次(9%)出现收缩压下降>10%,最大效应在30-45分钟,28/49(57%)患者出现该效应。
- 口服尼莫地平前后去甲肾上腺素使用率分别为3%和4%。
- 静脉或口服尼莫地平后均未观察到收缩压<90 mm Hg的低血压发作。
- 多因素分析调整入院Hunt & Hess评分、年龄、性别、机械通气、ICU入住天数及迟发性脑缺血后,仅基线收缩压较高与静脉(p<0.001)或口服(p=0.001)尼莫地平后收缩压下降>10%相关。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,静脉尼莫地平起始后及每10次口服摄入后需早期识别收缩压下降,并用升压药或液体对抗似乎是必要的,以预防低血压发作。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nimodipine is recommended to prevent delayed cerebral ischemia in patients with spontaneous subarachnoid hemorrhage (SAH). Here, we studied hemodynamic side effects of different nimodipine formulations (per os [PO] and intravenous [IV]) in patients with SAH undergoing continuous blood pressure monitoring.
METHODS: This observational cohort study includes consecutive patients with SAH (271 included in the IV group, 49 in the PO group) admitted to a tertiary care center between 2010 and 2021. All patients received prophylactic IV or PO nimodipine. Hemodynamic responses were evaluated based on median values within the first hour after continuous IV nimodipine initiation or PO nimodipine application (601 intakes within 15 days). Significant changes were defined as > 10% drop in systolic blood pressure (SBP) or diastolic blood pressure from baseline (median values 30 min before nimodipine application). With the use of multivariable logistic regression, risk factors associated with SBP drops were identified.
RESULTS: Patients were admitted with a median Hunt & Hess score of 3 (2-5; IV 3 [2-5], PO 1 [1-2], p < 0.001) and were 58 (49-69) years of age. Initiation of IV nimodipine was associated with a > 10% SBP drop in 30% (81/271) of patients, with a maximum effect after 15 min. A start or increase in noradrenaline was necessary in 136/271 (50%) patients, and colloids were administered in 25/271 (9%) patients within 1 h after IV nimodipine initiation. SBP drops > 10% occurred after 53/601 (9%) PO nimodipine intakes, with a maximum effect after 30-45 min in 28/49 (57%) patients. Noradrenaline application was uncommon (3% before and 4% after nimodipine PO intake). Hypotensive episodes to an SBP < 90 mm Hg were not observed after IV or PO nimodipine application. In multivariable analysis, only a higher SBP at baseline was associated with a > 10% drop in SBP after IV (p < 0.001) or PO (p = 0.001) nimodipine application, after adjusting for the Hunt & Hess score on admission, age, sex, mechanical ventilation, days after intensive care unit admission, and delayed cerebral ischemia.
CONCLUSIONS: Significant drops in SBP occur in one third of patients after the start of IV nimodipine and after every tenth PO intake. Early recognition and counteracting with vasopressors or fluids seems necessary to prevent hypotensive episodes.
参考来源
- Rass V, Kindl P, Lindner A, et al. Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage. Neurocrit Care. 2023. PMID: 37308727. doi:10.1007/s12028-023-01760-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。